Previous 10 | Next 10 |
Nhwa is conducting and funding this study to support NDA regulatory filing in China Trevena expects to receive approval and commercialization milestones, and a 10% royalty on net sales in China CHESTERBROOK, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (N...
Trevena (TRVN) has initiated a new study evaluating the physiologic impact of Olinvyk on respiratory function in elderly/obese subjects.Olinvyk is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatm...
-- Study is evaluating the role of age and weight in a comparative analysis of the effect of OLINVYK and morphine on respiratory function Led by world-renowned research group, utilizing an innovative PK / PD clinical utility function analysis method Enrollment expect...
Trevena (TRVN) shares slide over 10% during premarket trading after the company proposed a potential reverse stock split cutting the number of authorized shares by half to 100M.The company's stockholders are set to vote on the proposal at the upcoming special meeting scheduled in Au...
Greenland Technologies (GTEC) -13% after prices $7.0M underwritten public offering of ordinary shares.Alnylam Pharmaceuticals (ALNY) -10%.Trevena (TRVN) -10% on addition to Russell 2000, Russell 3000, and Russell Microcap Indexes.Atossa Therapeutics (ATOS) -10%.Exelixis (EXEL)&...
CHESTERBROOK, Pa., June 28, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced it has been added to the small-ca...
Oleksander Bontei/iStock via Getty Images Trevena (TRVN) has added ~5.0% in the pre-market after the company announced that the National Institute on Drug Abuse ((NIDA)), part of the NIH has resumed enrolling patients for its proof-of-concept study for TRV734. The company ...
-- TRV734 reduced drug-seeking behavior in a preclinical model of relapse, suggesting its utility as a novel oral maintenance treatment for opioid use disorder The study is being conducted and funded by the National Institute on Drug Abuse (NIDA), part of the NIH -- ...
CHESTERBROOK, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President and Chief Execu...
-- Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care -- CHESTERBROOK, Pa., May 19, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the de...
News, Short Squeeze, Breakout and More Instantly...
Trevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and commercialization milestones Trevena further expects a $10 million reduction in liabilities associated with its ex-US royalty financing ...
A look at the top 10 most actives in the United States SMX (Security Matters) Public Limited Company (SMX) rose 43.0% to $0.1702 on volume of 99,421,591 shares NVIDIA Corporation (NVDA) rose 3.5% to $140.3486 on volume of 71,277,917 shares MGO Global Inc. (MGOL) rose 222.9% to $1.48 on vo...
TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization TRV045 demonstrates statistically significant, dose-dependent increase in measures of seizure threshold and shows seizure protection in...